Intellia and Regeneron Present Updated Interim Data from Phase 1 Study of CRISPR-based NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis Demonstrating that Deep Serum TTR Reductions Remained Durable After a Single DosePRNewsWire • 06/24/22
Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the International Liver Congress™ 2022GlobeNewsWire • 06/08/22
Intellia Therapeutics, Inc. (NTLA) CEO John Leonard on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/05/22
Intellia Therapeutics Announces First Quarter 2022 Financial Results and Highlights Recent Company ProgressGlobeNewsWire • 05/05/22
Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its CRISPR-Engineered Allogeneic Platform at the 2022 Keystone Symposia's Precision Genome Engineering ConferenceGlobeNewsWire • 05/02/22
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2022 Earnings and Company UpdatesGlobeNewsWire • 04/28/22
Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-5001 for the Treatment of Acute Myeloid LeukemiaGlobeNewsWire • 03/09/22
Intellia Therapeutics Announces First Patient Dosed in Phase 1/2a Clinical Trial of NTLA-5001 for the Treatment of Acute Myeloid LeukemiaGlobeNewsWire • 03/01/22
Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing ProteinPRNewsWire • 02/28/22
Intellia and Regeneron Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing ProteinGlobeNewsWire • 02/28/22